Navigation Links
FDA Pulls Darvon and Companion Drug Due to Heart Risks
Date:11/20/2010

By Steven Reinberg
HealthDay Reporter

FRIDAY, Nov. 19 (HealthDay News) -- The opioid-based painkillers Darvon and Darvocet are being withdrawn from the U.S. market because they've been linked to serious and potentially deadly heart rhythms, federal officials said Friday.

The U.S. Food and Drug Administration said Xanodyne Pharmaceuticals -- which makes Darvon and Darvocet -- is voluntarily taking the drugs off the market. The active ingredient in these drugs is propoxyphene. The agency has also asked the makers of generic versions of propoxyphene to remove them from the market.

"We have recently completed our review of a new clinical trial that was designed to assess the impact of propoxyphene on the electrical activity of the heart," Dr. John Jenkins, director of FDA's Office of New Drugs, Center for Drug Evaluation and Research, said during a Friday press conference. The trial showed propoxyphene can cause potentially serious or even deadly heart rhythm problems, called arrhythmias, he said.

"We concluded the pain benefits of propoxyphene no longer outweighed the heart risk and that propoxyphene should no longer be sold in the United States," Jenkins said.

In 2009, the European Medicines Agency recommended withdrawing the drug across the European Union. A phased withdrawal is under way, the FDA said.

Dr. Gerald Dal Pan, director of the FDA's Office of Surveillance and Epidemiology, said the agency is asking doctors to stop prescribing propoxyphene.

"We are advising patients who are currently taking the drug not to stop taking propoxyphene right away. You still need to manage your pain. Instead, we urge you to contact your health care professional as soon as possible to discuss switching to another pain-management therapy," he said.

Dal Pan said patients taking the drug who experience heart palpitations, dizziness or light-headedness should contact their doctor right away.

People who stop the drug suddenly may experience withdrawal effects, such as nausea, diarrhea, anxiety and shivering, he said. "That's why this should be done under the supervision of a medical professional," he added.

Dal Pan said that the heart effects of propoxyphene aren't cumulative, so once the drug is stopped the risk should go away.

In 2009, approximately 10 million people in the United States were taking propoxyphene, he said. The most widely prescribed version was Darvocet, he noted.

Propoxyphene was approved by the FDA in 1957, is sold by prescription under various names, including Darvon, or in combination with acetaminophen (Darvocet).

The FDA said it had been asked twice since 1978 to take propoxyphene off the market, but until now the agency believed the drug's benefits outweighed the risks.

In 2009, an FDA advisory committee voted 14 to 12 to remove the drug from the market.

Despite that 2009 recommendation, the FDA left the drug available, but required a new boxed warning on the label, alerting patients and doctors of the risk of a fatal overdose. The agency also required Xanodyne to conduct a new safety study of propoxyphene's impact on the heart.

Results of that study showed significant changes to the heart's electrical activity, which can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death, the FDA said.

In a news release issued after the FDA announcement, Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, said: "The announcement by the U.S. Food and Drug Administration that propoxyphene-containing products are finally going to be taken off the market -- because of dangers previously known and acted upon, with bans announced in the U.K. almost six years ago, and in Europe, almost 1.5 years ago -- is a serious indictment of the FDA's long-lasting unwillingness to protect people in this country from a deadly but barely effective painkiller."

Dr. William O'Neill, executive dean for clinical affairs at the University of Miami Miller School of Medicine, said he had a problem with the way the FDA handled drug withdrawals, recalls and warnings.

"I'm a little annoyed, because what always happens with these drug recalls is that they tell patients to see their doctor, which puts the onus on doctors to help each individual patient make a decision about the benefit of the drug versus the potential side effects," O'Neill said.

Practicing physicians have no basis to make an informed decision, because they have not seen that data on which the FDA made its decision, O'Neill said. "I have no way of getting that information; it's not in any published journal," he said. "I have to infer from the nanny state that this is what's best -- I know what's right -- without being able to determine whether the drug is of value or not."

More information

For more on pain medications, visit the U.S. National Library of Medicine.

SOURCES: Nov. 19, 2010, teleconference with John Jenkins, M.D., director, Office of New Drugs, Center for Drug Evaluation and Research, and Gerald Dal Pan, M.D., M.H.S., director, Office of Surveillance and Epidemiology, both with the U.S. Food and Drug Administration; Nov. 19, 2010, news release, Public Citizen, Washington, D.C.; William O'Neill, M.D., executive dean, clinical affairs, University of Miami Miller School of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Christian Companion Senior Care Named to 2010 Hot 100 List
2. Homecare Homebase Optimizes PointCare Software for Celio Corp's REDFLY Mobile Companion
3. Flagship Biosciences Partners with a Leading IHC CLIA Laboratory for Companion Diagnostics Service
4. ICU Patients at Risk for Rare Heart Rhythm Problem
5. Cook With Love This Valentines Day With Heart-Smart Recipes
6. Study finds racial gaps continue in heart disease awareness
7. Highmark Foundation Awards $120,000 to the American Heart Association
8. Womens Heart Disease Awareness Still Lacking
9. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
10. Migraine Linked to Increased Heart Attack Risk
11. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology: